Alexander G Mathioudakis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4634136/publications.pdf

Version: 2024-02-01

100 papers

2,300 citations

279487 23 h-index 253896 43 g-index

106 all docs

106
docs citations

106 times ranked 3098 citing authors

#	Article	IF	Citations
1	ERS clinical practice guidelines on treatment of sarcoidosis. European Respiratory Journal, 2021, 58, 2004079.	3.1	248
2	The need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2170-2184.	2.7	219
3	GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. Journal of Clinical Epidemiology, 2017, 87, 14-22.	2.4	124
4	Impact of COVID-19 on Pediatric Asthma: Practice Adjustments and Disease Burden. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2592-2599.e3.	2.0	117
5	Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey. Life, 2021, 11, 249.	1.1	98
6	Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax, 2020, 75, 520-527.	2.7	97
7	Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. European Respiratory Review, 2017, 26, 160073.	3.0	93
8	How to keep good clinical records. Breathe, 2016, 12, 369-373.	0.6	86
9	GRADE Guidelines 30: the GRADE approach to assessing the certaintyÂof modeled evidence—An overview in the context of healthÂdecision-making. Journal of Clinical Epidemiology, 2021, 129, 138-150.	2.4	81
10	COVID-19 and COPD: a narrative review of the basic science and clinical outcomes. European Respiratory Review, 2020, 29, 200199.	3.0	73
11	Childhood asthma outcomes during the COVIDâ€19 pandemic: Findings from the PeARL multiâ€national cohort. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1765-1775.	2.7	62
12	Prevalence and burden of comorbidities in Chronic Obstructive Pulmonary Disease. Respiratory Investigation, 2016, 54, 387-396.	0.9	60
13	Interventions to improve inhaler technique for people with asthma. The Cochrane Library, 2022, 2022, CD012286.	1.5	57
14	Systematic review on women's values and preferences concerning breast cancer screening and diagnostic services. Psycho-Oncology, 2019, 28, 939-947.	1.0	48
15	Impact of longâ€term treatment with lowâ€dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: Aggravating or beneficial?. Respirology, 2013, 18, 147-153.	1.3	42
16	Chronic obstructive pulmonary disease and COVID-19: interrelationships. Current Opinion in Pulmonary Medicine, 2022, 28, 76-83.	1.2	42
17	Chronic Obstructive Pulmonary Disease and Stroke. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 405-413.	0.7	35
18	ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. European Respiratory Journal, 2022, 59, 2102006.	3.1	34

#	Article	lF	CITATIONS
19	Comparison of tumor markers and inflammatory biomarkers in chronic obstructive pulmonary disease (COPD) exacerbations. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 126-132.	0.6	33
20	Expression of Bmi1, FoxF1, Nanog, and \hat{I}^3 -Catenin in Relation to Hedgehog Signaling Pathway in Human Non-small-Cell Lung Cancer. Lung, 2013, 191, 511-521.	1.4	31
21	Developing trustworthy recommendations as part of an urgent response (1–2Âweeks): a GRADE concept paper. Journal of Clinical Epidemiology, 2021, 129, 1-11.	2.4	29
22	Research Priorities in Pediatric Asthma: Results of a Global Survey of Multiple Stakeholder Groups by the Pediatric Asthma in Real Life (PeARL) Think Tank. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1953-1960.e9.	2.0	27
23	Relationship of Allergy with Asthma: There Are More Than the Allergy "Eggs―in the Asthma "Basket― Frontiers in Pediatrics, 2017, 5, 92.	0.9	26
24	Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis. Respiratory Research, 2017, 18, 196.	1.4	26
25	Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD. European Respiratory Journal, 2020, 55, 1902119.	3.1	26
26	What is the impact of GOLD 2017 recommendations in primary care? – a descriptive study of patient classifications, treatment burden and costs. International Journal of COPD, 2018, Volume 13, 3485-3492.	0.9	21
27	Transfusion-Transmitted Malaria: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases, 2019, 6, ofz283.	0.4	21
28	Management of COVID-19-Associated Acute Respiratory Failure with Alternatives to Invasive Mechanical Ventilation: High-Flow Oxygen, Continuous Positive Airway Pressure, and Noninvasive Ventilation. Diagnostics, 2021, 11, 2259.	1.3	21
29	Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials. ERJ Open Research, 2019, 5, 00072-2019.	1.1	20
30	Screening, Diagnostic and Prognostic Tests for COVID-19: A Comprehensive Review. Life, 2021, 11, 561.	1.1	19
31	Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: Are they equivalent?. Pulmonary Pharmacology and Therapeutics, 2014, 28, 91-97.	1.1	17
32	EARLY versus MILD Chronic Obstructive Pulmonary Disease (COPD). Respiratory Medicine, 2018, 140, 127-131.	1.3	17
33	COVID-19 Clinical Trials: Unraveling a Methodological Gordian Knot. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 635-637.	2.5	17
34	A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations. ERJ Open Research, 2019, 5, 00136-2019.	1.1	15
35	Tiotropium HandiHaler Improves the Survival of Patients with COPD: A Systematic Review and Meta-Analysis. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2014, 27, 43-50.	0.7	14
36	ERS/EAACI statement on adherence to international adult asthma guidelines. European Respiratory Review, 2021, 30, 210132.	3.0	14

#	Article	IF	Citations
37	Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol. ERJ Open Research, 2020, 6, 00193-2020.	1.1	14
38	Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013198.	1.5	13
39	Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease. Drugs, 2021, 81, 1821-1830.	4.9	13
40	Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 226-234.	0.7	12
41	Triglyceride-Glucose Index in Non-Diabetic, Non-Obese Patients with Obstructive Sleep Apnoea. Journal of Clinical Medicine, 2021, 10, 1932.	1.0	12
42	Multidimensional indices in the assessment of chronic obstructive pulmonary disease. Respiratory Medicine, 2021, 185, 106519.	1.3	12
43	Laboratory Cross-Contamination of Mycobacterium tuberculosis: A Systematic Review and Meta-analysis. Lung, 2019, 197, 651-661.	1.4	11
44	Outcomes Evaluated in Controlled Clinical Trials on the Management of COVID-19: A Methodological Systematic Review. Life, 2020, 10, 350.	1.1	11
45	Transmission of SARS-CoV-2 in educational settings in 2020: a review. BMJ Open, 2022, 12, e058308.	0.8	11
46	Current developments and future directions in COPD. European Respiratory Review, 2020, 29, 200289.	3.0	10
47	The DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETwork (DECODE-NET): rationale and vision. European Respiratory Journal, 2020, 56, 2000627.	3.1	10
48	Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2020, 41, 463-474.	0.8	9
49	Prevalence and clinical implications of respiratory viruses in stable chronic obstructive pulmonary disease (COPD) and exacerbations: a systematic review and meta-analysis protocol. BMJ Open, 2020, 10, e035640.	0.8	9
50	Automated lung sound analysis using the LungPass platform: a sensitive and specific tool for identifying lower respiratory tract involvement in COVID-19. European Respiratory Journal, 2021, 58, 2101907.	3.1	9
51	Continuous versus intermittent antibiotics for bronchiectasis. The Cochrane Library, 2018, 2018, CD012733.	1.5	8
52	Interventions to improve inhaler technique and adherence to inhaled corticosteroids in children with asthma. Paediatric Respiratory Reviews, 2017, 23, 53-55.	1.2	7
53	Ashtma-Chronic obstructive pulmonary disease overlap syndrome (ACOS): current evidence and future research directions. COPD Research and Practice, 2017, 3, .	0.7	7
54	Stigma: an unmet public health priority in COPD. Lancet Respiratory Medicine, the, 2021, 9, 955-956.	5.2	7

#	Article	IF	CITATIONS
55	Comparison of the Level of Awareness about the Transmission of Echinococcosis and Toxocariasis between Pet Owners and Non-Pet Owners in Greece. International Journal of Environmental Research and Public Health, 2020, 17, 5292.	1.2	6
56	Assessing Treatment Success or Failure as an Outcome in Randomised Clinical Trials of COPD Exacerbations. A Meta-Epidemiological Study. Biomedicines, 2021, 9, 1837.	1.4	6
57	The emerging Chinese COPD epidemic. Lancet, The, 2018, 391, 1642-1643.	6.3	5
58	Research highlights from the 2017 ERS International Congress: airway diseases in focus. ERJ Open Research, 2018, 4, 00163-2017.	1.1	5
59	Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials. Respiratory Research, 2021, 22, 155.	1.4	5
60	Management of Stable COPD: An Update. Current Respiratory Medicine Reviews, 2014, 9, 352-359.	0.1	5
61	Tiotropium Inhaler Devices: Seeking Convenience When Mortality Is at Stake?. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2013, 26, 120-120.	0.7	4
62	Impact of self-reported environmental mould exposure on COPD outcomes. Pulmonology, 2023, 29, 375-384.	1.0	4
63	Intermittent prophylactic antibiotics for bronchiectasis. The Cochrane Library, 2022, 2022, CD013254.	1.5	4
64	The risk of tachyarrhythmias in patients with moderate-to-severe chronic kidney disease receiving tiotropium bromide. International Journal of Cardiology, 2015, 197, 105-106.	0.8	3
65	Research highlights from the 2018 European Respiratory Society International Congress: airway disease. ERJ Open Research, 2019, 5, 00225-2018.	1.1	3
66	Was the implementation strategy of the ProACT trial adequately proactive?. Breathe, 2019, 15, 77-80.	0.6	3
67	ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly. ERJ Open Research, 2020, 6, 00341-2019.	1.1	3
68	Adrenal suppression in patients with chronic obstructive pulmonary disease treated with glucocorticoids: Role of specific glucocorticoid receptor polymorphisms. PLoS ONE, 2022, 17, e0262898.	1.1	3
69	Chronic bronchitis: an objective diagnosis of exclusion. European Respiratory Journal, 2012, 40, 1305.1-1305.	3.1	2
70	Continuous versus intermittent antibiotics for non-cystic fibrosis bronchiectasis. The Cochrane Library, 2017, , .	1.5	2
71	Management of asthma in childhood: study protocol of a systematic evidence update by the Paediatric Asthma in Real Life (PeARL) Think Tank. BMJ Open, 2021, 11, e048338.	0.8	2
72	Late Breaking Abstract - Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids , 2018, , .		2

#	Article	IF	Citations
73	Obstructive Sleep Apnea and Hypertension: A Bidirectional Causal Relation. Current Respiratory Medicine Reviews, 2015, 11, 272-277.	0.1	2
74	Overlap Syndrome of Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea: A Two-Faced Janus. Current Respiratory Medicine Reviews, 2015, 11, 308-313.	0.1	2
7 5	Outcomes assessed in therapeutic randomized controlled trials in hospitalized patients with COVID-19: is the meta Core Outcome Set (meta-COS) adopted?. Clinical Microbiology and Infection, 2022, 28, 456-457.	2.8	2
76	Inspiring stories: the impact that being part of ERS activities can have on a professional career. Breathe, 2022, 18, 210217.	0.6	2
77	Serum procalcitonin can guide antibiotic administration for respiratory tract infections in primary care. BMJ, The, 2016, 354, i4245.	3.0	1
78	Valvular-CHADS-VASc as a safer alternative to CHADS-VASc score. International Journal of Cardiology, 2016, 221, 1051-1052.	0.8	1
79	Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis. The Cochrane Library, 0, , .	1.5	1
80	Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial. Respiratory Research, 2020, 21, 263.	1.4	1
81	GOLD ABCD assessment tool: Comparison of 2013 and 2017 classifications in the UK Clinical Practice Research Datalink (CPRD)., 2018,,.		1
82	COPD Phenotypes and Biomarkers: Introducing Personalised Medicine. Current Respiratory Medicine Reviews, 2014, 9, 372-378.	0.1	1
83	Intermittent prophylactic antibiotics for bronchiectasis. The Cochrane Library, 0, , .	1.5	1
84	Drugs that Act on the Respiratory Tract. Side Effects of Drugs Annual, 2014, 36, 241-256.	0.6	О
85	P51â€Clinical effectiveness of procalcitonin based protocols to guide the administration of antibiotics in patients presenting with COPD exacerbations: systematic review and meta-analysis. Thorax, 2016, 71, A110-A111.	2.7	O
86	Early Career Members at the ERSÂInternational Congress London 2016. Breathe, 2016, 12, 364-368.	0.6	0
87	Opportunities for early careerÂmembers. Breathe, 2017, 13, 127-128.	0.6	O
88	ERS Early Career Members meet EAACI Junior Members: the launch of a strong, fruitful collaboration. Breathe, 2017, 13, 231-233.	0.6	0
89	Airways diseases: insights from the European Respiratory Society Annual Congress 2017. Journal of Thoracic Disease, 2017, 9, S1550-S1553.	0.6	O
90	Capsule Commentary on Bremmer et. al., Impact of Procalcitonin Guidance on Management of Adults Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations. Journal of General Internal Medicine, 2018, 33, 749-749.	1.3	0

#	Article	IF	CITATIONS
91	Capsule Commentary on Ashburner et al., Electronic Physician Notifications to Improve Guideline-Based Anticoagulation in Atrial Fibrillation: a Randomized Controlled Trial. Journal of General Internal Medicine, 2018, 33, 2190-2190.	1.3	0
92	Biomarkers to guide antibiotic therapy for COPD exacerbations. The Cochrane Library, $0, , .$	1.5	O
93	P190â€Systematic survey of reported outcomes in ventilator associated pneumonia randomised controlled trials. , 2021, , .		O
94	The association between beta-blocker therapy and daytime sleepiness in obstructive sleep apnoea. Sleep and Biological Rhythms, 2021, 19, 399-408.	0.5	0
95	Corticosteroid Resistance in Smokers—A Substudy Analysis of the CORTICO-COP Randomised Controlled Trial. Journal of Clinical Medicine, 2021, 10, 2734.	1.0	O
96	Editorial from Guest Editor (Thematic Issue: Current Approach to COPD Management: Setting a Model) Tj ETQq	0 0 0.1gBT	Oyerlock 10
97	Prevalence of metabolic syndrome among patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. , 2015, , .		О
98	Estimating potential cost savings associated with managing COPD according to GOLD 2017 recommendations in UK primary care: a CPRD study. , 2018 , , .		0
99	Methodology of clinical trials in COPD exacerbations: Eligibility criteria and endpoint selection , 2018, , .		O
100	The use of beta-blockers is not associated with increased daytime sleepiness in patients with obstructive sleep apnoea. , 2019 , , .		O